Anti-Butyrylcholinesterase

The Centers for Disease Control and Prevention (CDC) intends to award a sole-source purchase order to Fisher Scientific, located in Hanover Park, IL, for the provision of a monoclonal butyrylcholinesterase antibody. This procurement will be conducted using other than full and open competition, under the authority of FAR 13.106-1(b)(1), and follows Simplified Acquisition Procedures as outlined in FAR Part 13 and guidelines of FAR Part 12 for commercial items. The acquisition falls under NAICS code 424210, with a small business size standard of 500 employees. Although this notice is not a request for competitive proposals, the CDC encourages interested parties to submit a capabilities statement to demonstrate their ability to provide the required antibody, with all responses considered at the discretion of the Contracting Officer. Awarding this contract as a sole source reflects the CDC's intention to negotiate and finalize the agreement exclusively with Fisher Scientific. The point of contact for this contract is Deborah T. Workman, who can be reached via email at [email hidden] or by phone at [phone hidden]. This notice reinforces that the determination to forego competition rests solely with the Contracting Officer, and the CDC may decide based on the responses received whether or not to proceed without a formal competitive process.